Becton, Dickinson and Company

$59.24 USD

-$1.36 (-2.24%)

Volume: 6.15M
Average Volume: 0
Market Capitalization: $55.91B
P/E Ratio: 40.16
Dividend Yield: 2.36%
Price Target

Year High: $64.12
Year Low: $49.07
Day High: —
Day Low: —
Payout Ratio: $1.04
Current Ratio: $0.94

Industry, Sector & symbol

Stock Exchange	NYSE
CEO	Thomas E. Polen Jr.
Industry	Medical - Instruments & Supplies
Sector	Healthcare
Current Symbol	BDXA
CUSIP	075887109
CIK	0000010795
Web	https://www.bd.com
Phone	201 847 6800
Currency	USD
Employees	72000
Country	US

Liquidity

Debt-to-Equity Ratio	0.72
Payout Ratio	1.04
Current Ratio	0.94
Quick Ratio	0.55
Cash Ratio	0.10

Sales & Book Value

Annual Sales	$21.84B
Price / Sales	2.69
Cash Flow	11.20
Price / Cash Flow	18.29
Price / Book	1.84

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecast Upside/Downside	%
Consensus Rating	N/A
Rating Score(0-5)	0
Research Coverage	0 Analysts

Profitability

EPS (Most Recent Fiscal Year)	$5.83
Trailing P/E Ratio	40.16
PEG Ratio	-1.62
P/E Growth	-1.62
Net Income	$1.68B
Net Margin	5.33%
Pretax Margin	8.14%
Return on Equity	4.54%
Return on Assets	2.24%

Financials Score

AltmanZ Score	2.12
Piotroski Score	7.00
Working Capital	837M
Total Assets	54.9B
Ebit	2.5B
Market Cap	55.91B
Total Liabilities	29.43B

Poll Results

About Becton, Dickinson and Company (NYSE:BDXA) Stock

Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including ... needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.

Becton, Dickinson: Value Or Overvalued Even Now?

2026-04-20 06:35:45

Becton, Dickinson is rated a 'BUY' under $160/share, driven by attractive fundamentals and a conservative valuation approach. Despite the recent spin-off of its high-margin bioscience segment, BDX retains core medtech operations with solid profitability and robust cash flow generation. I see BDX's current 13x P/E as undervalued, with a fair value target of $215/share by 2028E and an annualized return above 15% at current prices.

Frequently Asked Questions

What is the current Becton, Dickinson and Company (BDXA) stock price?: Becton, Dickinson and Company(NYSE:BDXA) stock price is $59.24 in the last trading session. During the trading session, BDXA stock reached the peak price of $64.12 while $49.07 was the lowest point it dropped to. The percentage change in BDXA stock occurred in the recent session was --2.24% while the dollar amount for the price change in BDXA stock was -$1.36.
BDXA's industry and sector of operation?: The NYSE listed BDXA is part of Medical - Instruments & Supplies industry that operates in the broader Healthcare sector.
Who are the executives of BDXA?: |
|
|
|
|
How many employees does BDXA have?: Number of BDXA employees currently stands at 72000. BDXA operates from 1 Becton Drive, Franklin Lakes, NJ 07417-1880, US.

Link for BDXA official website?: Official Website of BDXA is: https://www.bd.com
How do I contact BDXA?: BDXA could be contacted at phone #201 847 6800 and can also be accessed through its website. BDXA operates from 1 Becton Drive, Franklin Lakes, NJ 07417-1880, US.
How many shares of BDXA are traded daily?: The average number of BDXA shares traded daily for last 3 months was 0.
What is the market cap of BDXA currently?: The market value of BDXA currently stands at $55.91B with its latest stock price at $59.24